Cassava Sciences Inc

SAVA

NASDAQ. Currency in USD

38.10 -0.60 ( -1.55% )

Real time prices: December 19

Market Cap.
1.59B
Beta (5Y monthly)
0.03
Price/Earnings
-
EPS (TTM)
-1.78
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Dec 17, 2012
Volume
713,619
1y Target Est.
69.75
Day's Range
37.06
-
38.76
52 Week's Range
13.84
-
62.49

Historical Summary

Performance
EPS growth
Share Buybacks

About Cassava Sciences Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.cassavasciences.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
40.02M
Employees
24
Address
7801 North Capital of Texas Highway, Austin, TX, United States, 78731
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Latest news

Is Anavex Life Sciences a Buy?
Is Anavex Life Sciences a Buy?

It still needs to prove that its lead program is as effective as it claims...
By The Motley Fool - 7 weeks ago

Tesla, Apple,  GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today

U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee...
By Benzinga - 8 weeks ago

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage...
By GlobeNewswire Inc. - 8 weeks ago

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”...
By GlobeNewswire Inc. - 10 weeks ago

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”...
By GlobeNewswire Inc. - 11 weeks ago

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

– $174.7 Million Cash and Cash Equivalents at September 30, 2022 –
By GlobeNewswire Inc. - 12 weeks ago

Short sellers hit back at Cassava lawsuit against them: ‘We stand behind everything we wrote’
Short sellers hit back at Cassava lawsuit against them: ‘We stand behind everything we wrote’

The defendants at the heart of a lawsuit from meme stock Cassava have hit back...
By MarketWatch - 13 weeks ago

Short sellers hit back at Cassava lawsuit against them: ‘We stand behind everything we wrote’
Short sellers hit back at Cassava lawsuit against them: ‘We stand behind everything we wrote’

The defendants at the heart of a lawsuit from meme stock Cassava have hit back...
By MarketWatch - 13 weeks ago